Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

References for PMC Articles for PubMed (Select 22234262)

1.

Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question.

Hope TJ.

Nat Med. 2011 Oct 11;17(10):1195-7. doi: 10.1038/nm.2528. No abstract available.

PMID:
21988997
2.

AIDS research. Novel antibody response may explain HIV vaccine success.

Cohen J.

Science. 2011 Sep 16;333(6049):1560. doi: 10.1126/science.333.6049.1560. No abstract available.

PMID:
21921167
3.

Measurements of immune responses for establishing correlates of vaccine protection against HIV.

Burgers WA, Manrique A, Masopust D, McKinnon LR, Reynolds MR, Rolland M, Blish C, Chege GK, Curran R, Fischer W, Herrera C, Sather DN.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):641-8. doi: 10.1089/AID.2011.0239. Epub 2011 Sep 23.

4.

Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.

Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, Lopez M, Kemelman M, Ginsberg AA, Mullen K, Coleman JW, Wu CD, Narpala S, Ouellette I, Dean HJ, Lin F, Sardesai NY, Cassamasa H, McBride D, Felber BK, Pavlakis GN, Schultz A, Hudgens MG, King CR, Zamb TJ, Parks CL, McDermott AB.

J Virol. 2011 Sep;85(18):9578-87. doi: 10.1128/JVI.05060-11. Epub 2011 Jul 6.

5.

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.

Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, Yeh WW, Asmal M, Gelman RS, Shen L, Whitney JB, Seoighe C, Lacerda M, Keating S, Norris PJ, Hudgens MG, Gilbert PB, Buzby AP, Mach LV, Zhang J, Balachandran H, Shaw GM, Schmidt SD, Todd JP, Dodson A, Mascola JR, Nabel GJ.

Sci Transl Med. 2011 May 4;3(81):81ra36. doi: 10.1126/scitranslmed.3002351.

6.

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ; HIV Vaccine Trials Network of NIAID.

J Infect Dis. 2011 Apr 15;203(8):1165-73. doi: 10.1093/infdis/jiq175.

7.

Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Antibody Dilution Method.

Mascola JR.

Methods Mol Med. 1999;17:309-15. doi: 10.1385/0-89603-369-4:309.

PMID:
21380682
8.

Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara.

Manrique M, Kozlowski PA, Cobo-Molinos A, Wang SW, Wilson RL, Montefiori DC, Mansfield KG, Carville A, Aldovini A.

J Immunol. 2011 Mar 15;186(6):3581-93. doi: 10.4049/jimmunol.1002594. Epub 2011 Feb 11.

9.

Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.

Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, Devillier G, Cong Z, Wei Q, Gao H, Qin C, Yang GB, Zurbriggen R, Lopalco L, Fleury S.

Immunity. 2011 Feb 25;34(2):269-80. doi: 10.1016/j.immuni.2011.01.015.

10.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31.

11.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

12.

Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV.

Makedonas G, Betts MR.

Immunol Rev. 2011 Jan;239(1):109-24. doi: 10.1111/j.1600-065X.2010.00968.x. Review.

13.

High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation.

Yin J, Dai A, Lecureux J, Arango T, Kutzler MA, Yan J, Lewis MG, Khan A, Sardesai NY, Montefiore D, Ruprecht R, Weiner DB, Boyer JD.

Vaccine. 2011 Sep 9;29(39):6763-70. doi: 10.1016/j.vaccine.2010.12.055. Epub 2010 Dec 31.

PMID:
21195801
14.

Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.

Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ.

Vaccine. 2011 Feb 4;29(7):1421-30. doi: 10.1016/j.vaccine.2010.12.034. Epub 2010 Dec 25.

15.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

16.

Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.

Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S.

PLoS One. 2010 Nov 9;5(11):e13916. doi: 10.1371/journal.pone.0013916.

17.

Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.

Siddappa NB, Hemashettar G, Wong YL, Lakhashe S, Rasmussen RA, Watkins JD, Novembre FJ, Villinger F, Else JG, Montefiori DC, Ruprecht RM.

J Med Primatol. 2011 Apr;40(2):120-8. doi: 10.1111/j.1600-0684.2010.00454.x. Epub 2010 Nov 2.

18.

Induction of immunity to human immunodeficiency virus type-1 by vaccination.

McElrath MJ, Haynes BF.

Immunity. 2010 Oct 29;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011. Review.

19.

HIV vaccines: lessons learned and the way forward.

Kim JH, Rerks-Ngarm S, Excler JL, Michael NL.

Curr Opin HIV AIDS. 2010 Sep;5(5):428-34. doi: 10.1097/COH.0b013e32833d17ac. Review.

20.

Strategies for eliciting HIV-1 inhibitory antibodies.

Tomaras GD, Haynes BF.

Curr Opin HIV AIDS. 2010 Sep;5(5):421-7. doi: 10.1097/COH.0b013e32833d2d45. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk